Compare AR & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AR | CRL |
|---|---|---|
| Founded | 2002 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 10.9B |
| IPO Year | 2013 | 1999 |
| Metric | AR | CRL |
|---|---|---|
| Price | $33.50 | $228.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 12 |
| Target Price | $47.13 | ★ $198.27 |
| AVG Volume (30 Days) | ★ 4.8M | 839.0K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1027.78 | N/A |
| EPS | ★ 1.72 | N/A |
| Revenue | ★ $5,275,823,000.00 | $1,857,601,000.00 |
| Revenue This Year | $29.74 | N/A |
| Revenue Next Year | $5.07 | $3.04 |
| P/E Ratio | $19.75 | ★ N/A |
| Revenue Growth | ★ 21.97 | 10.48 |
| 52 Week Low | $29.10 | $144.26 |
| 52 Week High | $45.75 | $237.86 |
| Indicator | AR | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 41.08 | 66.13 |
| Support Level | $32.85 | $218.39 |
| Resistance Level | $35.86 | $231.30 |
| Average True Range (ATR) | 1.02 | 8.71 |
| MACD | -0.04 | -0.26 |
| Stochastic Oscillator | 23.33 | 72.39 |
Antero Resources is an exploration and production firm whose operations represent a pure play in the Marcellus Shale, located in northern West Virginia. The company started in 2002 as an E&P focused on the Barnett Shale (Fort Worth, Texas). Antero redefined itself in Appalachia's Marcellus Shale in 2005. In 2012, shortly before Antero's 2013 IPO, Antero Midstream Partners was formed to handle the company's rapidly growing gas volumes. In 2026, the firm narrowed its focus further by selling its Ohio Utica assets and using the proceeds to acquire additional Marcellus acreage from HG Energy. Just over half of its production and earning power is tied to natural gas, with the remainder mostly NGLs, where it holds a leading position, and some crude oil.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.